Combining lenacapavir (LEN, Gilead) and two broadly neutralizing antibodies (bNAbs) could be a good option for HIV treatment in certain patients, according to results of a phase 2 trial presented at EACS 2025, in Paris.
The investigators (abstract…
Novel HIV combo therapy of lenacapavir and 2 bNAbs found effective, well tolerated in Phase 2 trial
